Wednesday, June 19 at 12:00pm to 1:00pm
Zilkha Neurogenetic Institute (ZNI), 112
1501 San Pablo, Los Angeles, CA 90033
The development of radiotracers binding to fibrillary deposits of beta-amyloid (in the mid-2000s) and paired helical filaments of tau (in the mid-2010s) has provided the unprecedented opportunity to visualize the neuropathological landmarks of Alzheimer’s disease (AD) in living patients.
I will first present recent investigations of the relationships between in vivo PET and post mortem findings to better characterize the neuropathological underpinnings of PET signal. I will then illustrate the interest of PET to describe the mechanisms of AD pathophysiology and to study the drivers of clinical heterogeneity in AD (e.g., Are there differences between early- and late-onset AD? Why does AD sometimes manifest as a non-amnestic syndrome?). Finally, the presentation will highlight the promise of PET in clinical trials, for both patient stratification and target engagement.